SR

Active Director Director DIN 10142214
DIN 10142214 First appointment Apr 2023 Primary industry Paper
Unlock full profile Investments · shareholding · contact details
Current companies 1 active board seats
Total affiliations 1 Since Apr 2023
Shareholding value •••• Premium profile

About Sonam Rai

Data last updated:

Sonam Rai is a Director at Medgaraz Pharmaceuticals Private Limited (since 2023). The company operates in Paper. Medgaraz Pharmaceuticals Private Limited reported revenue of ₹36.6 Lakh (FY 2025).

DIN 10142214
Primary Designation Director
Industry Paper
First Appointment 30 Apr 2023
Oldest Company Age 3 yrs
Largest company Medgaraz Pharmaceuticals Private Limited · ₹36.6 Lakh (FY 2025)

Current companies

CompanyDesignationAppointmentFoundedRevenueStatus
Director30 Apr 20232023₹36.6 Lakh (FY 2025)Active

Directorship timeline

Open interactive timeline →
Medgaraz Pharmaceuticals Private Limited
Premium access

Shareholding and investment profile for Sonam Rai

Company-level share counts, filed values, and quarterly changes require authenticated premium access.

  • Company-level holdings
  • Filed share counts
  • Reported values
  • Quarterly changes
Unlock shareholding

Verified entity values are shown only after access is granted.

Frequently Asked Questions about Sonam Rai

Sonam Rai currently holds 1 directorship: Medgaraz Pharmaceuticals Private Limited (Director, since 30 Apr 2023, revenue ₹36.6 Lakh (FY 2025)).

Sonam Rai was first appointed on 30 Apr 2023 as Director at Medgaraz Pharmaceuticals Private Limited.

The current boards of Sonam Rai's companies include Narendra Yadav (Medgaraz Pharmaceuticals Private Limited), Suryakant Tripathi (Medgaraz Pharmaceuticals Private Limited), Veerenda Dixit (Medgaraz Pharmaceuticals Private Limited).

Explore millions of companies — effortlessly

Access structured, verified intelligence on 7M+ companies across industries, sectors, and global markets. From early-stage startups to large enterprises, discover ownership, leadership, funding, financials, acquisitions, and market signals — all in one powerful platform.

Free account with essential features Instant access to company reports Enterprise solutions available